Pila Pharma AB Company Description

Pila Pharma AB (publ) operates as a clinical stage biotech company in Sweden.

The company develops XEN-D0501, a TRPV1 antagonist in Phase 2a trial for obesity, diabetes, and heart failure; Phase 1 trial for erythromelalgia, inflammation pain, and rare diseases; and preclinical trial for abdominal aorta aneurism and cardiovascular diseases.

Pila Pharma AB (publ) was incorporated in 2014 and is headquartered in Malmö, Sweden.

Pila Pharma AB (publ)

Country	Sweden
Founded	2014
Industry	Biotechnology
Sector	Healthcare
Employees	1
CEO	Gustav Gram

Contact Details

Address: Norra Vallgatan 72 Malmö, 211 22 Sweden
Phone	46 7 39 03 69 69
Website	pilapharma.com

Stock Details

Ticker Symbol	PILA
Exchange	Nasdaq Stockholm
Fiscal Year	January - December
Reporting Currency	SEK
ISIN Number	SE0015988274
SIC Code	2834

Key Executives

Name	Position
Gustav Hanghoj Gram	Chief Executive Officer
Dorte Xenia Gram	Founder, Chairman and Chief Scientific Officer
Hampus Darrell	Chief Financial Officer
Miguel Lecumberri	Head of Compliance and Legal Affairs
Masoud Alavi	Head of Corporate Visual Communication
Andy Makin	Head of Toxicology
Maura McArdle	Head of BD and Quay Pharma
Mike Frodsham	Chief Technology Officer of Quay Pharma
Alison Foster	Head of Pre-Clinical - Quay Pharma
Simon Hamilton	Head of Global Business Development - Almac